Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 38,043 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 38,043 shares of the company’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $0.89, for a total transaction of $33,858.27. Following the transaction, the director owned 3,158,420 shares of the company’s stock, valued at approximately $2,810,993.80. The trade was a 1.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Luke Evnin also recently made the following trade(s):

• On Thursday, December 4th, Luke Evnin sold 53,416 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.97, for a total transaction of $51,813.52.
• On Wednesday, December 3rd, Luke Evnin sold 36,726 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.87, for a total transaction of $31,951.62.
• On Monday, December 1st, Luke Evnin sold 39,096 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total transaction of $36,750.24.
• On Friday, November 28th, Luke Evnin sold 13,014 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.99, for a total value of $12,883.86.
• On Wednesday, November 26th, Luke Evnin sold 38,978 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total value of $38,198.44.
• On Tuesday, November 25th, Luke Evnin sold 27,297 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.92, for a total value of $25,113.24.
• On Monday, November 24th, Luke Evnin sold 56,992 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total value of $55,852.16.
• On Friday, November 21st, Luke Evnin sold 41,287 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.83, for a total value of $34,268.21.
• On Thursday, November 20th, Luke Evnin sold 26,411 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total value of $23,505.79.
• On Wednesday, November 19th, Luke Evnin sold 42,566 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total transaction of $40,012.04.

Werewolf Therapeutics Price Performance

Shares of NASDAQ:HOWL traded down $0.01 on Friday, reaching $0.98. 67,889 shares of the company were exchanged, compared to its average volume of 502,483. The company has a 50-day moving average of $1.40 and a 200-day moving average of $1.33. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. The firm has a market cap of $47.67 million, a price-to-earnings ratio of -0.61 and a beta of 0.74. Werewolf Therapeutics, Inc. has a 1-year low of $0.60 and a 1-year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.03. Equities analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on HOWL. Zacks Research cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Citigroup reiterated a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. JMP Securities dropped their price target on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Thursday, August 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Finally, Bank of America lowered their price objective on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $7.75.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of institutional investors have recently made changes to their positions in HOWL. Susquehanna International Group LLP lifted its position in shares of Werewolf Therapeutics by 16.9% in the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after acquiring an additional 13,439 shares in the last quarter. MPM Bioimpact LLC raised its stake in Werewolf Therapeutics by 0.9% in the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after purchasing an additional 20,799 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Werewolf Therapeutics by 33.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock valued at $93,000 after purchasing an additional 23,852 shares in the last quarter. MPM Asset Management LLC lifted its holdings in Werewolf Therapeutics by 0.6% in the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after purchasing an additional 25,688 shares in the last quarter. Finally, Quadrature Capital Ltd acquired a new stake in shares of Werewolf Therapeutics during the 2nd quarter worth about $28,000. 64.84% of the stock is owned by institutional investors and hedge funds.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.